BOR
| Response . | Cohort A (BV naive) (n = 63) . | Cohort B (BV after auto-HCT) (n = 80) . | Cohort C (BV before and/or after auto-HCT) (n = 100) . | Overall (N = 243) . |
|---|---|---|---|---|
| ORR, % (95% CI) | 65.1 (52.0-76.7) | 71.3 (60.0-80.8) | 75.0 (65.3-83.1) | 71.2 (65.1-76.8) |
| BOR, n (%) | ||||
| CR | 20 (31.7) | 11 (13.8) | 21 (21.0) | 52 (21.4) |
| PR | 21 (33.3) | 46 (57.5) | 54 (54.0) | 121 (49.8) |
| SD | 14 (22.2) | 14 (17.5) | 12 (12.0) | 40 (16.5) |
| Progressive disease | 8 (12.7) | 7 (8.8) | 11 (11.0) | 26 (10.7) |
| Median time to response, mo (range) | 2.0 (1.5-4.6) | 2.2 (1.6-11.1) | 2.1 (0.8-17.9) | 2.1 (0.8-17.9) |
| IQR | 1.9–2.3 | 1.9–3.0 | 1.9–3.8 | 1.9–3.6 |
| Median time to CR, mo (range) | 3.9 (1.7-34.4) | 4.4 (1.9-22.8) | 4.2 (1.8-17.9) | 4.0 (1.7-34.4) |
| IQR | 3.7–5.2 | 3.7–19.1 | 3.7–6.5 | 3.7–8.3 |
| Median DOR, mo (95% CI) | 26.2 (15.2–NE) | 16.6 (9.3-25.7) | 18.2 (11.6-30.9) | 18.2 (14.7-26.1) |
| Response . | Cohort A (BV naive) (n = 63) . | Cohort B (BV after auto-HCT) (n = 80) . | Cohort C (BV before and/or after auto-HCT) (n = 100) . | Overall (N = 243) . |
|---|---|---|---|---|
| ORR, % (95% CI) | 65.1 (52.0-76.7) | 71.3 (60.0-80.8) | 75.0 (65.3-83.1) | 71.2 (65.1-76.8) |
| BOR, n (%) | ||||
| CR | 20 (31.7) | 11 (13.8) | 21 (21.0) | 52 (21.4) |
| PR | 21 (33.3) | 46 (57.5) | 54 (54.0) | 121 (49.8) |
| SD | 14 (22.2) | 14 (17.5) | 12 (12.0) | 40 (16.5) |
| Progressive disease | 8 (12.7) | 7 (8.8) | 11 (11.0) | 26 (10.7) |
| Median time to response, mo (range) | 2.0 (1.5-4.6) | 2.2 (1.6-11.1) | 2.1 (0.8-17.9) | 2.1 (0.8-17.9) |
| IQR | 1.9–2.3 | 1.9–3.0 | 1.9–3.8 | 1.9–3.6 |
| Median time to CR, mo (range) | 3.9 (1.7-34.4) | 4.4 (1.9-22.8) | 4.2 (1.8-17.9) | 4.0 (1.7-34.4) |
| IQR | 3.7–5.2 | 3.7–19.1 | 3.7–6.5 | 3.7–8.3 |
| Median DOR, mo (95% CI) | 26.2 (15.2–NE) | 16.6 (9.3-25.7) | 18.2 (11.6-30.9) | 18.2 (14.7-26.1) |
NE, not evaluable; SD, stable disease.